Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH)

• Status: Completed
• Trial end date: 1994-06-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess the efficacy and safety of orally administered hydroxyurea in the treatment of painful crises in patients with sickle cell anemia.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
• Treatments: Hydroxyurea

Criteria

Men and women, ages 18 to 50, who had at least three emergency room visits or hospitalizations for sickle cell anemia during the year prior to recruitment. Patients with greater than 20 crises per year were included. A total of 295 patients had Hb ss and four had Hb SB thalassemia.